Herein, with the largest clinical cohort to date, we demonstrate that SETD2-mutated lung adenocarcinoma presents at a significantly earlier stage and trends towards improved recurrence-free survival in early-stage tumors. The gene discussed is SETD2; the disease is lung adenocarcinoma.